# A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer

> **NCT06320067** · PHASE3 · RECRUITING · sponsor: **University College, London** · enrollment: 3360 (estimated)

## Conditions studied

- Prostate Cancer Metastatic

## Interventions

- **RADIATION:** Stereotactic Ablative Body Radiotherapy (SABR)
- **OTHER:** 177Lu-PSMA-617
- **DRUG:** Androgen Deprivation Therapy (ADT)
- **DRUG:** Androgen Receptor Signalling Inhibitor (ARPI)
- **RADIATION:** Radiotherapy to Prostate ± Pelvic Nodes
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT06320067
- **Lead sponsor:** University College, London
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-11
- **Primary completion:** 2031-04
- **Final completion:** 2032-03
- **Target enrollment:** 3360 (ESTIMATED)
- **Last updated:** 2025-09-26

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06320067

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06320067, "A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06320067. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*